Skip to main content

textochbilcontainer

A BUSINESS MODEL WITH FASTER TIME TO MARKET AND LOWER DEVELOPMENT RISK COMPARED WITH CONVENTIONAL DRUG DEVELOPMENT

textochbilcontainer

OUR CLINICAL pipeline CONSISTS of late stage drug candidates with a combined peak sales potential estimated at USD 350–700

textochbilcontainer

Moberg pharma intends to submit a registration application in Europe in 2021.

Moberg Pharma is a rapidly growing Swedish pharmaceutical company commercializing proprietary, acquired and licensed products in the global market. Initially, the company specialized in the treatment of skin diseases, with a focus on treatments for nail fungus.

Stockvalue 2013-05-20 14:00
32,90 kr
+2,5 %

Subscribe

Get our latest press releases and reports

 

Latest report

2020-08-11 Interim report April – June 2020

Calendar/presentations

Next calendar event: 2020-11-10 Interim report for July 2019 - September 2020

Redemption of shares

On November 26, 2019, a payment of SEK 46.50 per share was made through redemption of shares.

Mycological cure rate after MOB-015 treatment, Phase 3 data

...